GH Research (NASDAQ:GHRS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS – Get Rating) in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a $45.00 target price on the stock.

GHRS has been the subject of several other reports. UBS Group initiated coverage on GH Research in a research note on Thursday, December 15th. They issued a buy rating for the company. EF Hutton Acquisition Co. I reaffirmed a buy rating and set a $33.00 target price on shares of GH Research in a report on Thursday, March 2nd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of Buy and an average target price of $46.25.

GH Research Stock Up 0.7 %

Shares of NASDAQ:GHRS opened at $8.72 on Monday. GH Research has a 52-week low of $8.01 and a 52-week high of $20.32. The stock has a market cap of $440.53 million, a price-to-earnings ratio of -20.28 and a beta of 0.80. The business has a 50-day moving average price of $9.66 and a 200-day moving average price of $10.87.

Institutional Trading of GH Research

Several hedge funds and other institutional investors have recently bought and sold shares of GHRS. Verition Fund Management LLC grew its holdings in GH Research by 47.6% in the fourth quarter. Verition Fund Management LLC now owns 897,860 shares of the company’s stock valued at $8,682,000 after purchasing an additional 289,736 shares during the period. VR Adviser LLC grew its holdings in GH Research by 5.5% in the fourth quarter. VR Adviser LLC now owns 3,517,125 shares of the company’s stock valued at $34,186,000 after purchasing an additional 183,971 shares during the period. Millennium Management LLC grew its holdings in GH Research by 585.8% in the fourth quarter. Millennium Management LLC now owns 69,339 shares of the company’s stock valued at $671,000 after purchasing an additional 59,228 shares during the period. Morgan Stanley grew its holdings in GH Research by 7.1% in the fourth quarter. Morgan Stanley now owns 524,115 shares of the company’s stock valued at $5,094,000 after purchasing an additional 34,779 shares during the period. Finally, Citadel Advisors LLC grew its holdings in GH Research by 2.2% in the second quarter. Citadel Advisors LLC now owns 1,303,470 shares of the company’s stock valued at $13,009,000 after purchasing an additional 27,738 shares during the period. 62.55% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

(Get Rating)

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).